WAM
RVNC

Wolverine Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Wolverine Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,200
Closed -$18.8K – 1865
2024
Q4 		$18.8K Hold
6,200
– – ﹤0.01% 1299
2024
Q3 		$32.2K Buy
6,200
+4,000
+182% +$19.9K ﹤0.01% 1220
2024
Q2 		$5.65K Hold
2,200
– – ﹤0.01% 1389
2024
Q1 		$10.8K Hold
2,200
– – ﹤0.01% 1288
2023
Q4 		$19.3K Hold
2,200
– – ﹤0.01% 1320
2023
Q3 		$25.2K Buy
+2,200
New +$42.3K ﹤0.01% 1330

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wolverine Asset Management's RVNC Position: Q1 2025 in Review

Wolverine Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 192,103 shares — an estimated $584K sold.

Wolverine Asset Management first reported a position in RVNC in Q1 2021 and held it in 6 quarters. The position peaked at $1.2M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Wolverine Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Wolverine Asset Management sold 192,103 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $584K.
  • Wolverine Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2021 and held it in 6 quarters.
  • Wolverine Asset Management's Revance Therapeutics, Inc. position peaked at $1.2M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Wolverine Asset Management's 13F filing for Q1 2025, filed 12 May 2025.